Excision repair cross complementation group 1 polymorphisms and lung cancer risk： a meta-analysis

Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 （ERCC1） enzyme and lung cancer risk in diverse populations but with conflicting results.By pooling the relatively small samples in each study, it is possible to perform a meta-analysis of the evidence by rigorous methods.Methods Embase, Ovid, Medline and Chinese National Knowledge Infrastructure were searched. Additional studies were identified from references in original studies or review articles. Articles meeting the inclusion criteria were reviewed systematically, and the reported data were aggregated using the statistical techniques of meta-analysis.Results We found 3810 cases with lung cancer and 4332 controls from seven eligible studies. T19007C polymorphism showed no significant effect on lung cancer risk （C allele vs. T allele： odds ratio （OR）=0.91, 95% confidence interval （CI）=0.80-1.04; CC vs. TT： OR=0.76, 95% CI=0.56-1.02; CC vs. （CT＋TT）： OR=0.96, 95% CI=-0.84-1.10）. Similarly,there was no significant main effects for T19007C polymorphism on lung cancer risk when stratified analyses by ethnicity （Chinese or Caucasian）. No significant association was found between C8092A polymorphism （3060 patients and 2729 controls） and the risk of lung cancer （A allele vs. C allele： OR=1.03, 95% CI=0.95-1.11; AA vs. CC： OR=1.08, 95% CI=-0.88-1.33; AA vs. （AC＋CC）： OR=1.08, 95% CI=-0.88-1.31）.Conclusion We found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people.

ERCC1 expression in patients with colorectal cancer:a pilot study

Aim:Excision repair cross complementation group 1(ERCC1)has a key role in enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer(CRC)patients.Hence,the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC.Methods:ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients.Results:ERCC1 codon 118 C/T polymorphism analysis reported the predominance of C/T(52%)genotype as compared to C/C(38%)and T/T(10%)genotypes.Furthermore,72%of patients showed positive ERCC1 protein expression.Significant correlation was not observed between clinicopathological parameters and ERCC1 polymorphism,while ERCC1 protein expression significantly correlated only with tumor site(colon vs.rectum)(P=0.046).Further,the present study failed to demonstrate the role of ERCC1 C118T polymorphism or protein expression as useful prognostic markers in CRC patients.Conclusion:ERCC1-positive protein expression may be a useful marker for rectal cancer patients.However,further evaluation in a larger set of CRC patients is required to better understand the role of ERCC1.